

Product Information

Product ID S0168

CAS No. 379231-04-6

Chemical Name N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine

Synonym AZD-0530

Formula C₂₇H₃₂ClN₅O₅

Formula Wt. 542.03

Melting Point


Purity ≥98%

Solubility

Store Temp Ambient

Ship Temp Ambient

Description Saracatinib is an inhibitor of Src and Abl family kinases that is used for its anticancer chemotherapeutic and immunomodulatory benefits. Saracatinib is currently in clinical trials as a potential treatment for a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, and myeloma. In cellular and animal models, this compound inhibits migration, invasion, and growth of cancer cells. Additionally, saracatinib displays mixed immunomodulatory effects, decreasing T cell cytokine production in one in vitro model and increasing CD8⁺ memory T cells and production of IFN-γ in another in vitro model.



Bulk quantities available upon request

Product ID	Size
S0168	1 mg
S0168	5 mg
S0168	25 mg

References Gangadhar TC, Clark JI, Karrison T, et al. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. *Invest New Drugs*. 2013 Jun;31(3):769-73. PMID: 23151808.

Nam HJ, Im SA, Oh DY, et al. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. *Mol Cancer Ther*. 2013 Jan;12(1):16-26. PMID: 23144237.

Cavalloni G, Peraldo-Neia C, Sarotto I, et al. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. *Mol Cancer Ther*. 2012 Jul;11(7):1528-38. PMID: 22452946.

Takai S, Sabzevari H, Farsaci B, et al. Distinct effects of saracatinib on memory CD8⁺ T cell differentiation. *J Immunol*. 2012 May 1;188(9):4323-33. PMID: 22450814.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.